BioCentury
ARTICLE | Clinical News

Coenzyme Q10: Phase II

October 21, 2002 7:00 AM UTC

In a placebo-controlled U.S. Phase II trial in 80 patients, those given 1,200 mg/day of coenzyme Q10 (largest dose) had 44% less decline in mental function, motor function and ability to carry out act...